You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Immunogenicity of panitumumab in combination chemotherapy clinical trials
|
|---|---|
| Published in |
BMC Clinical Pharmacology, November 2011
|
| DOI | 10.1186/1472-6904-11-17 |
| Pubmed ID | |
| Authors |
Dohan Weeraratne, Alin Chen, Jason J Pennucci, Chi-Yuan Wu, Kathy Zhang, Jacqueline Wright, Juan José Pérez-Ruixo, Bing-Bing Yang, Arunan Kaliyaperumal, Shalini Gupta, Steven J Swanson, Narendra Chirmule, Marta Starcevic |
| Abstract |
Panitumumab is a fully human antibody against the epidermal growth factor receptor that is indicated for the treatment of metastatic colorectal cancer (mCRC) after disease progression on standard chemotherapy. The purpose of this analysis was to examine the immunogenicity of panitumumab and to evaluate the effect of anti-panitumumab antibodies on pharmacokinetic and safety profiles in patients with mCRC receiving panitumumab in combination with oxaliplatin- or irinotecan-based chemotherapies. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Hungary | 1 | 2% |
| Unknown | 47 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 27% |
| Student > Bachelor | 5 | 10% |
| Student > Master | 5 | 10% |
| Other | 3 | 6% |
| Student > Ph. D. Student | 3 | 6% |
| Other | 6 | 13% |
| Unknown | 13 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 29% |
| Agricultural and Biological Sciences | 7 | 15% |
| Immunology and Microbiology | 3 | 6% |
| Biochemistry, Genetics and Molecular Biology | 3 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
| Other | 6 | 13% |
| Unknown | 13 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 November 2011.
All research outputs
#14,721,336
of 22,656,971 outputs
Outputs from BMC Clinical Pharmacology
#45
of 56 outputs
Outputs of similar age
#94,559
of 142,895 outputs
Outputs of similar age from BMC Clinical Pharmacology
#6
of 7 outputs
Altmetric has tracked 22,656,971 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 56 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.1. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 142,895 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one.